甲状腺结节分子检测：是否已准备好投入使用？
Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?
机构信息
Surgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States.
出版信息
Front Endocrinol (Lausanne). 2020 Oct 9;11:590128. doi: 10.3389/fendo.2020.590128. eCollection 2020.
Abstract
Cytologically indeterminate thyroid nodules remain a diagnostic and clinical challenge, and molecular testing has been advocated and advanced as a diagnostic modality to help guide treatment. While studies have expounded on the improved diagnostic certainty with these tests, data demonstrating meaningful clinical impact and supporting their routine use is still limited at best. In this review, we discuss the limitations regarding diagnostic accuracy, impact on surgical decision-making and outcomes, and cost-effectiveness of molecular testing. By highlighting the limitations of these tests, we aim to promote more thoughtful utilization of these tools in the management of thyroid nodules going forward.
摘要
甲状腺细胞学不确定结节仍然是一个诊断和临床挑战，分子检测被提倡并作为一种诊断方法来帮助指导治疗。虽然研究已经阐述了这些测试在提高诊断确定性方面的改进，但证明具有有意义的临床影响并支持其常规使用的数据仍然是有限的。在这篇综述中，我们讨论了分子检测在诊断准确性、对手术决策和结果的影响以及成本效益方面的局限性。通过强调这些测试的局限性，我们旨在促进在未来甲状腺结节管理中更明智地利用这些工具。
相似文献
1
Thyroid Nodule Molecular Testing: Is It Ready for Prime Time?甲状腺结节分子检测：是否已准备好投入使用？
Front Endocrinol (Lausanne). 2020 Oct 9;11:590128. doi: 10.3389/fendo.2020.590128. eCollection 2020.
2
An update on the status of molecular testing for the indeterminate thyroid nodule and risk stratification of differentiated thyroid cancer.甲状腺结节性质不明时分子检测现状及分化型甲状腺癌风险分层的最新进展
Curr Opin Oncol. 2018 Jan;30(1):8-15. doi: 10.1097/CCO.0000000000000414.
3
Role of gene expression profiling in defining indeterminate thyroid nodules in addition to BRAF analysis.除BRAF分析外，基因表达谱在确定甲状腺结节性质不明确中的作用。
Cancer Cytopathol. 2016 May;124(5):340-9. doi: 10.1002/cncy.21681. Epub 2016 Jan 7.
4
Decision Making in Indeterminate Thyroid Nodules and the Role of Molecular Testing.甲状腺结节的诊断决策与分子检测的作用。
Surg Clin North Am. 2019 Aug;99(4):587-598. doi: 10.1016/j.suc.2019.04.002. Epub 2019 May 9.
5
Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.甲状腺结节不明原因的分子检测：Afirma 基因表达分类器和 ThyroSeq 面板的性能。
Cancer Cytopathol. 2018 Jul;126(7):471-480. doi: 10.1002/cncy.21993. Epub 2018 Apr 10.
6
7
Molecular Testing for Thyroid Nodules Including Its Interpretation and Use in Clinical Practice.甲状腺结节的分子检测：包括其解读及在临床实践中的应用。
Ann Surg Oncol. 2021 Dec;28(13):8884-8891. doi: 10.1245/s10434-021-10307-4. Epub 2021 Jul 18.
8
The role of molecular diagnostic testing in the management of thyroid nodules.分子诊断检测在甲状腺结节管理中的作用。
Expert Rev Mol Diagn. 2017 Jun;17(6):567-576. doi: 10.1080/14737159.2017.1321987. Epub 2017 Apr 28.
9
UTILITY OF ULTRASOUND VERSUS GENE EXPRESSION CLASSIFIER IN THYROID NODULES WITH ATYPIA OF UNDETERMINED SIGNIFICANCE.超声与基因表达分类器在不明确意义的甲状腺结节中的应用。
Endocr Pract. 2016 Oct;22(10):1199-1203. doi: 10.4158/EP161231.OR. Epub 2016 Jul 13.
10
Clinical Experience of Cytologically Indeterminate Thyroid Nodules Designated as Negative on Molecular Testing Using ThyroSeq V3: A Retrospective Cohort Study.使用ThyroSeq V3分子检测判定为阴性的细胞学意义不明确的甲状腺结节的临床经验：一项回顾性队列研究
Thyroid. 2023 May;33(5):641-644. doi: 10.1089/thy.2022.0555. Epub 2023 Mar 28.
引用本文的文献
1
Molecular Testing in Thyroid Nodules: How Much Does It Change Clinical Practice?甲状腺结节的分子检测：它对临床实践有多大改变？
Biomedicines. 2025 Aug 9;13(8):1947. doi: 10.3390/biomedicines13081947.
2
Clinical and Pathologic Characteristics of Cytologically Indeterminate Thyroid Nodules with Non-V600E Alterations.具有非V600E改变的细胞学不确定甲状腺结节的临床和病理特征
Cancers (Basel). 2025 Feb 22;17(5):741. doi: 10.3390/cancers17050741.
3
A Scoping Review of Patient Health-Related Quality of Life Following Surgery or Molecular Testing for Individuals with Indeterminate Thyroid Nodules.对甲状腺结节性质不明的个体进行手术或分子检测后患者健康相关生活质量的范围综述
Healthcare (Basel). 2024 Oct 11;12(20):2025. doi: 10.3390/healthcare12202025.
4
Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules.多基因小 DNA 面板有助于降低甲状腺结节的手术切除率并预测其恶性风险。
Endocrinol Metab (Seoul). 2024 Oct;39(5):777-792. doi: 10.3803/EnM.2024.2034. Epub 2024 Oct 14.
5
Role of Genetic Testing in the Management of Indeterminate Thyroid Nodules in the Indian Setting.基因检测在印度环境下不确定甲状腺结节管理中的作用。
Indian J Endocrinol Metab. 2024 Jan-Feb;28(1):3-10. doi: 10.4103/ijem.ijem_415_23. Epub 2024 Feb 26.
6
Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis.具有 RET 和 NTRK 融合基因的甲状腺癌的临床病理分析：遗传分析特征。
Virchows Arch. 2024 Sep;485(3):509-518. doi: 10.1007/s00428-024-03777-w. Epub 2024 Mar 12.
7
Diagnostic Accuracy of the Bethesda System for Reporting Thyroid Cytopathology (TBSRTC): An Institution Experience.甲状腺细胞病理学报告的贝塞斯达系统（TBSRTC）的诊断准确性：一项机构经验。
Int J Endocrinol. 2023 Nov 15;2023:9615294. doi: 10.1155/2023/9615294. eCollection 2023.
8
Pilot Study on the Use of Untargeted Metabolomic Fingerprinting of Liquid-Cytology Fluids as a Diagnostic Tool of Malignancy for Thyroid Nodules.利用液体细胞学液的非靶向代谢组学指纹图谱作为甲状腺结节恶性肿瘤诊断工具的初步研究。
Metabolites. 2023 Jun 23;13(7):782. doi: 10.3390/metabo13070782.
9
Artificial Intelligence in Thyroidology: A Narrative Review of the Current Applications, Associated Challenges, and Future Directions.人工智能在甲状腺学中的应用：当前应用、相关挑战及未来方向的叙述性综述。
Thyroid. 2023 Aug;33(8):903-917. doi: 10.1089/thy.2023.0132. Epub 2023 Jun 26.
10
Artificial Intelligence Role in Subclassifying Cytology of Thyroid Follicular Neoplasm.人工智能在甲状腺滤泡肿瘤细胞学分类中的作用。
Asian Pac J Cancer Prev. 2023 Apr 1;24(4):1379-1387. doi: 10.31557/APJCP.2023.24.4.1379.
本文引用的文献
1
Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.甲状腺癌中端粒酶逆转录酶（TERT）的调控：综述。
Front Endocrinol (Lausanne). 2020 Jul 31;11:485. doi: 10.3389/fendo.2020.00485. eCollection 2020.
2
ThyroSeq v2 Testing: Impact on Cytologic Diagnosis, Management, and Cost of Care in Patients with Thyroid Nodule.甲状腺测序 v2 检测：对甲状腺结节患者的细胞学诊断、管理和医疗费用的影响。
Thyroid. 2020 Oct;30(10):1528-1534. doi: 10.1089/thy.2019.0191. Epub 2020 Jun 19.
3
The Role of the ThyroSeq v3 Molecular Test in the Surgical Management of Thyroid Nodules in the Canadian Public Health Care Setting.在加拿大公共医疗保健环境中，甲状腺结节手术管理中 ThyroSeq v3 分子检测的作用。
Thyroid. 2020 Sep;30(9):1280-1287. doi: 10.1089/thy.2019.0539. Epub 2020 May 5.
4
Long-Term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience.甲状腺结节 AFIRMA GEC 检测的长期结果及文献复习：机构经验。
Otolaryngol Head Neck Surg. 2020 May;162(5):634-640. doi: 10.1177/0194599820911718. Epub 2020 Mar 17.
5
The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.美国内分泌外科学会成人甲状腺疾病确定性手术管理指南。
Ann Surg. 2020 Mar;271(3):e21-e93. doi: 10.1097/SLA.0000000000003580.
6
Executive Summary of the American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults.美国内分泌外科医师协会成人甲状腺疾病确定性外科治疗指南执行摘要。
Ann Surg. 2020 Mar;271(3):399-410. doi: 10.1097/SLA.0000000000003735.
7
Utilities of Mutations in Preoperative Fine Needle Biopsies for Decision Making for Thyroid Nodule Management: Results from a Single-Center Prospective Cohort.术前细针穿刺活检中突变的效用对甲状腺结节管理决策的影响：来自单中心前瞻性队列研究的结果。
Thyroid. 2020 Apr;30(4):536-547. doi: 10.1089/thy.2019.0116. Epub 2020 Feb 20.
8
Real-world Comparison of Afirma GEC and GSC for the Assessment of Cytologically Indeterminate Thyroid Nodules.基于临床数据对比评估 Afirma GEC 与 GSC 系统在甲状腺细针穿刺细胞学不确定病例中的应用。
J Clin Endocrinol Metab. 2020 Mar 1;105(3). doi: 10.1210/clinem/dgz099.
9
Surgery alone for papillary thyroid microcarcinoma is less costly and more effective than long term active surveillance.手术单独治疗甲状腺微小乳头状癌的成本更低，效果优于长期主动监测。
Surgery. 2020 Jan;167(1):110-116. doi: 10.1016/j.surg.2019.05.078. Epub 2019 Sep 19.
10
Selective use of Molecular Testing Based on Sonographic Features of Cytologically Indeterminate Thyroid Nodules: A Decision Analysis.基于细胞学不确定甲状腺结节超声特征的分子检测的选择性应用：决策分析。
World J Surg. 2020 Feb;44(2):393-401. doi: 10.1007/s00268-019-05177-7.
Zotero 插件